T-VEC, a genetically engineered herpes virus, has proven to be effective immunotherapy for patients with melanoma in a Phase 3 clinical trial.
Aug 3, 2015 1:00:33 PM / by Karina Palomares posted in Cancer Immunology, cancer immunotherapy, clinical trial, melanoma, oncolytic virus
T-VEC, a genetically engineered herpes virus, has proven to be effective immunotherapy for patients with melanoma in a Phase 3 clinical trial.